Hernexeos (zongertinib tablets - Boehringer Ingelheim) — Cigna
Non-Small Cell Lung Cancer (unresectable or metastatic, HER2 [ERBB2] activating mutation)
Initial criteria
- Patient is age ≥ 18 years; AND
- Patient has unresectable or metastatic disease; AND
- Patient has human epidermal growth factor receptor 2 (HER2) [ERBB2] activating mutation; AND
- The mutation was detected by an approved test; AND
- Patient has received at least one prior systemic therapy
Approval duration
1 year